The shares of the British pharmaceutical company AstraZeneca are cheaper for the third day in a row because of uncertainty about the effectiveness of its COVID-19 vaccine. This is evidenced by trading data.
Shares of AstraZeneca cheaper by 0.66% to 79.47 pounds sterling, and since the beginning of the week they have lost 4.4% of the value.
On Monday, AstraZeneca said that an interim analysis of clinical trials of the vaccine, developed jointly with scientists from Oxford, showed an average efficiency of 70%. According to the data from the pharmaceutical company, the participants received two different dosage options for the vaccine, one of them showed efficiency at 90% and the other at 62%.
Earlier Wednesday, Bloomberg Agency reported, citing Donald Trump Monceph Slowly, advisor to the administration of the current U.S. president, that the vaccine dosage, developed by AstraZeneca in conjunction with the University of Oxford, which showed high efficiency, was tested on volunteers under 55.
AstraZeneca Plc, one of the largest pharmaceutical companies in the world, was formed by the merger of British Zeneca Group Plc and Swedish Astra AB in 1999. The company develops, manufactures, and sells medicines for the treatment of gastrointestinal, cardiovascular, neurological, and oncological diseases.